Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : CLTR COULTER PHARMACEUTICAL -- Ignore unavailable to you. Want to Upgrade?

To: LLCF who wrote (600)	8/14/2000 9:11:03 AM
From: Russian Bear	Read Replies (1) \| Respond to of 666

It is not the announcement we have been expecting: biz.yahoo.com Monday August 14, 8:30 am Eastern Time Press Release Coulter Pharmaceutical Announces $35.8 Million Private Placement SOUTH SAN FRANCISCO, Calif.--(BW HealthWire)--Aug. 14, 2000-- Coulter Pharmaceutical, Inc. (Nasdaq:CLTR - news) today announced that it has entered into definitive purchase agreements for the sale of 1,655,000 shares of newly issued common stock to selected institutional and other accredited investors for approximately $35.8 million. The purchase price was $21.625 per share. The shares of common stock have not been registered under the Securities Act of 1933, as amended, and may not be offered or sold in the United States absent registration, or an applicable exemption from registration. Pacific Growth Equities, Inc. served as the placement agent for this transaction. The Company intends to use net proceeds from this private placement to fund its commercialization efforts as well as its research and development activities including additions to personnel, pre-clinical studies, clinical trials, and manufacturing. etc. etc.